The global healthcare cold chain third-party logistics market, valued at USD 45.78 billion in 2025, is projected to expand to USD 97.47 billion by 2035. This growth represents a robust compound annual growth rate (CAGR) of 7.85%, driven by increasing demand for temperature-sensitive pharmaceuticals and vaccines.
Healthcare Cold Chain Third Party Logistics Market Statical Scope
| Reports Attributes |
Statistics |
| Market Size in 2025 |
USD 45.78 Billion |
| Market Size in 2026 |
USD 49.37 Billion |
| Market Size in 2032 |
USD 77.7 Billion |
| Market Size by 2035 |
USD 97.47 Billion |
| CAGR 2026 to 2035 |
7.85% |
| Base Year |
2025 |
| Forecast Period |
2026 to 2035 |
The healthcare cold chain third-party logistics market is expected to grow from USD 45.80 billion in 2025, with a CAGR of 7.85%. The massive rise and expansion of this market is led by strict regulatory compliance and the acceleration of biologics to support specialty medicines. Alongside the tech integration, there is a strength to this market.
The healthcare cold chain third-party logistics (3PL) is a comprehensive, unique service involving healthcare companies trusting the storage space and transportation capacity of the essential, temperature-based products with the logistics team. The outsourcing of these sensitive products highly relies on the smart logistics team. The fundamental services are temperature-balanced warehousing, real-time monitoring, and specialized transportation. The popular market players (providers) like UPS Healthcare and DHL Group are known for the expansion and acquisition potential flowing into this market.
The business of 3PLS is a rapid profit as the healthcare sector is never at a halt in any product outsourcing. This bolsters healthcare trading and more space for tech-driven drug delivery approaches to meet the patient demand in real time. The growing adoption of CGT, based on the number of cases, needs cryogenic storage. Alongside, extending the trial period leverages the requirement for storage, especially for international cold chain distribution.
Healthcare Cold Chain Third Party Logistics Market Share, By Region, 2025 (%)
| Regions |
Shares (%) |
| North America |
39% |
| Europe |
26% |
| Asia-Pacific |
22% |
| Latin America |
7% |
| Middle East & Africa |
6% |
- North America – North America is leading with 39% of market share due to the timely digitized involvement and contribution from regional leaders. The expansion and new tech adoption rate are at peak with the same.
- Europe – Europe’s investment strategy in infrastructure, largely in cold storage and transport vehicles, brings 26% of market share, elevating the regional market profit. The constant pump to the outsourcing with the in-house transition efforts in pharmaceuticals is paving the way for more opportunities in the market.
- Asia-Pacific – Asia Pacific is another leading region with 22% of market share, with a high investment rate in infrastructure. This signals spectacular modernized logistics infrastructure and GMP-compliant warehouses.
- Latin America – Latin America is in the queue with 7% of the market share, with its steady and effective initiatives for tech-driven solutions in reframing the regional healthcare logistics infrastructure.
- Middle East & Africa – MEA tends to see a rise in technology with a clear focus on the pharmaceutical sector, as the requirement is accelerating with the growing health conditions. The region secures 6% of the market share with its valuable alliances in this market.
Healthcare Cold Chain Third Party Logistics Market Share, By Service, 2025 (%)
| Segments |
Shares (%) |
| Transportation |
43% |
| Packaging Solutions |
14% |
| Monitoring & Visibility Solutions |
12% |
| Warehousing & Storage |
21% |
| Inventory Management |
6% |
- Transportation – The transportation service segment led the market with 43% share and is attracting more precision in drug or vaccine delivery, and elevates the demand for sensitive temperature-based biologics. The air freight confirms the convenience and quick delivery of healthcare solutions to meet real-time patient care.
- Packaging Solutions – The packaging solutions segment holds he 14% of the market share, mainly for healthcare essential products, which are driven by strict regulatory compliance for responsible and sharp packaging, mainly for vaccines and medical devices. While the growth in biologics depends on accurate cold chain conditions.
- Monitoring & Visibility Solutions – With the 12% of the market share, this segment experiences steady and advanced growth, supporting advanced therapies. The involvement of predictive analytics, AI, real-time tracking, IoT, and blockchain for integrity is bringing more profit to this segment.
- Warehousing & Storage - The Warehousing & Storage service segment holds the 21% of market share due to its offering of cold storage facilities for both biologics and pharmaceuticals.
- Inventory Management - Inventory Management service segments holding 6% of share with a strong focus on management and tracking of stock levels across the whole supply chain.
Healthcare Cold Chain Third Party Logistics Market Share, By Product, 2025 (%)
| Segments |
Shares (%) |
| Biopharmaceuticals |
46% |
| Pharmaceuticals |
32% |
| Medical Device |
15% |
- Biopharmaceuticals – The biopharmaceuticals segment obtains 46% of market share due to the expansion of biologics and growing cell and gene therapy. This marks more storage demand for further availability.
- Pharmaceuticals – This segment hypes with 32% of the market share, due to rising demand for vaccines since the viral health conditions are at their peak. Following this, the transportation facility for temperature-based products is also in higher demand.
- Medical Device – The medical device segment range is accelerating with unique integrations of technology and advanced systems in the healthcare sector. The cold chain requirement, especially for temperature-sensitive medical devices, is increasing, with 15% of the market in this segment.
Healthcare Cold Chain Third Party Logistics Market Share, By Temperature Range, 2025 (%)
| Segments |
Shares (%) |
| Frozen |
48% |
| Ultra-frozen/Deep-Frozen |
28% |
| Cryogenic |
24% |
- Frozen – The need for frozen temperature is high in the cell and gene therapy sector, which is investing more in specialized containers, with the demand for very low temperature logistics. This segment is fundamental for biologics, blood plasma, and vaccines storage, holding 48% of the market share.
- Ultra-frozen/Deep-Frozen – The segment rises with 28% of market share, and a major boost to the expansion of biopharmaceuticals, which brings more profit to the cold chain because of the sensitive drugs, which are compulsorily stored in a deep-frozen environment.
- Cryogenic – The segment holding 150°C potential to manage CGT-based storage requirements and serving the cold chain services to rapidly growing clinical trials and biologics holds 24% of the market share.
Healthcare Cold Chain Third Party Logistics Market Share, By End Use, 2025 (%)
| Segments |
Shares (%) |
| Pharmaceutical & Biopharmaceutical Companies |
52% |
| Medical Device Companies |
28% |
| Others |
20% |
- Pharmaceutical & Biopharmaceutical Companies – The segment is leading with 52% of the market share with its sincere focus on outsourcing and delivering the biologics sector the best-in-class cold chain services.
- Medical Device Companies – The medical device companies' market share rose to 28%, with the dependency and responsibility on specialized 3PL providers to manage wearable sensors, implants, and diagnostic kits.
- Others – The connecting CROs, hospitals, blood banks, and diagnostic labs have acquired 20% of the market share with their consistent and urgent need for time-sensitive samples transportation. The demand for modernized logistics for biological samples and clinical trial materials is a popular demand from CROs.
Published by
Deepa Pandey
